Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Estimated changes in follow-up depressive symptoms associated with 60-minute reallocations from the mean baseline movement behaviour composition^b'*'. by Hugues Sampasa-Kanyinga (606145)

Subjects:

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Flow chart of participant inclusion from NHANES 2005–2018 surveys. by Vanessa K. Tassone (13190695)

Subjects:

Demographic characteristics of the NHANES 2005–2018 study population (<i>n</i> = 23,669), stratified by sex and employment status. by Vanessa K. Tassone (13190695)

Subjects:

Reason for unemployment among those unemployed in the study population, stratified by sex. by Vanessa K. Tassone (13190695)

Subjects:

Adjusted logistic regression of suicidal ideation and educational attainment, stratified by sex and employment status (study population). by Vanessa K. Tassone (13190695)

Subjects:

Adjusted logistic regression of depressive symptoms and educational attainment, stratified by sex and employment status (study population). by Vanessa K. Tassone (13190695)

Subjects:

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Plot of mean simulated power with 95 percentile (2.5 & 97.5%) for select DNAm differences. by Jacquelyn Y. Taylor (6386456)

Subjects:

High postpartum maternal depression, stress, and morning cortisol concentration significantly decrease Shannon’s Entropy in infant stool. by Johanna R. Jahnke (10833803)

Osr1 heterozygous mice experienced decreased bile acid synthesis in the liver. by Ernest C. Lynch (12769954)

“…(D) Osr1 heterozygous male mice had significantly decreased expression of <i>Cyp7a1</i>, <i>Cyp27a1</i>, <i>Ehhadh</i>, <i>Cyp4a10</i> and <i>Cyp4a14</i> compared to WT male mice. …”

Forest plot and subgroup analysis for raw mean difference of studies on the effects of relaxation interventions on depressive symptoms using EPDS. by Mubarek Abera (7288370)

Subjects:

Means (±SD) of the psychometric questionnaires of male and female participants with almost no fear, moderate fear and severe fear of COVID-19. by Patrick Nürnberger (12160940)

Subjects:

Manhattan plot for genome-wide association study (GWAS) in a European population with depression. by Xiaomei He (795333)

Subjects: